Skopos Labs, Inc. Allogene Therapeutics, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 30,731 shares of ALLO stock, worth $37,184. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,731
Previous 30,731
-0.0%
Holding current value
$37,184
Previous $44,000
22.73%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
170Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$22.6 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$19.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$13.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$13.4 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$12.7 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $174M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...